Loading…
Universe Pharmaceuticals INC is projected to decline to $5.33 by 2027, a -18% move from its current price of $6.48. UPC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $5.97 | $6.48 | $7.04 | +0.01% |
| Aug 6 | $5.77 | $6.48 | $7.28 | +0.01% |
| Aug 7 | $5.62 | $6.48 | $7.47 | +0.02% |
| Aug 8 | $5.50 | $6.48 | $7.64 | +0.03% |
| Aug 9 | $5.39 | $6.48 | $7.79 | +0.03% |
| Aug 10 | $5.30 | $6.48 | $7.93 | +0.04% |
| Aug 11 | $5.22 | $6.48 | $8.06 | +0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.22 | $6.48 | $8.06 | +0.05% |
| Week 2 | $4.77 | $6.49 | $8.82 | +0.10% |
| Week 3 | $4.45 | $6.49 | $9.45 | +0.14% |
| Week 4 | $4.20 | $6.49 | $10.03 | +0.19% |
| Week 5 | $4.00 | $6.50 | $10.56 | +0.24% |
| Week 6 | $3.82 | $6.50 | $11.07 | +0.29% |
| Week 7 | $3.66 | $6.50 | $11.55 | +0.33% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications.
It also provides guben yanling, shenrong weisheng, and quanlu pill; Yangxue danggui and qiangli pipa syrup; Wuzi yanzong oral, fengtong medicinal, shenrong medicinal, qishe medicinal, fengshitong medicinal, and shiquan dabu medicinal liquor; paracetamol granule for children; and isatis root granule. The company was founded in 1998 and is headquartered in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.
Universe Pharmaceuticals INC (UPC) operates in Healthcare. The current price is $3.39 and the market cap is $2.25M, with a rank of 5188.
Forecasts indicate a multi-year pathway with a 2026 average near the current price and meaningful upside into the 2030s and 2040s, culminating in a 2050 average of $10.74 and a max of $24.70. The 2030 forecast shows an average of $4.07 and a max of $7.05, while 2031 projects an average of $4.69 and a max of $8.42. ROI figures include 20 in 2030 and 38.3 in 2031, with 216.8 in 2050 at the long end of the curve.
The 30-day range is $1.86 to $6.17, reflecting notable near-term volatility along with a wide potential price band as shown in the forecast. These figures collectively outline a long-run upside path, even as near-term periods exhibit negative and neutral signals in some years.
A major floor 65.3% below — a decisive break under it would weaken the trend.
The nearest floor, 56.2% below — buyers have tended to step in here.
The nearest ceiling, 88.0% above — a clean break opens room to run.
A major ceiling 137.7% above — clearing it would confirm fresh momentum.
Key UPC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of UPC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.31 | Buy | $3.36 | Buy |
| MA 10 | $3.63 | Buy | $3.65 | Buy |
| MA 20 | $4.40 | Buy | $4.00 | Buy |
| MA 50 | $3.97 | Buy | $3.97 | Buy |
| MA 100 | $3.41 | Buy | $3.94 | Buy |
| MA 200 | $3.69 | Buy | $19.48 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.06 | Neutral |
| Stoch RSI (14) | 3.57 | Buy |
| CCI (20) | -107.29 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.20 | Sell |
| ROC (12) | -35.51 | Sell |
| Bollinger %B (20,2) | 0.17 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.27 | Sell |
| Awesome (5,34) | -1.04 | Sell |
| Ultimate (7,14,28) | 27.42 | Buy |
| Momentum (10) | -1.29 | Sell |
| Aroon Osc (25) | 8.00 | Buy |
| Hull MA (9) | 3.15 | Buy |
| ADX (14) | 11.00 | Neutral |
| ATR (14) | 0.44 | Info |
The 30-day technical picture is NEUTRAL.
RSI14 is 50, with the price trading below both the 50-day and 200-day simple moving averages (SMA50 = $3.89, SMA200 = $3.79). This alignment suggests a neutral to cautious short-term stance despite a balanced RSI reading.
Support is at $2.84 and resistance at $12.18, providing defined levels for potential price action. The 30-day range runs from $1.86 to $6.17, illustrating a wide intramonth trading band. Annualized volatility is high at 200%, underscoring elevated risk and substantial price swings.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.25 | $6.48 | $9.06 | 0% | Neutral | |
| $3.89 | $5.33 | $7.91 | -18% | Bearish | |
| $3.84 | $5.61 | $8.87 | -13% | Neutral | |
| $3.67 | $5.65 | $9.39 | -13% | Neutral | |
| $4.69 | $7.56 | $13.09 | +17% | Neutral | |
| $5.32 | $8.97 | $16.08 | +38% | Bullish | |
| $3.99 | $7.03 | $12.99 | +8% | Neutral | |
| $3.74 | $6.85 | $13.02 | +6% | Neutral | |
| $3.85 | $7.34 | $14.31 | +13% | Neutral | |
| $3.30 | $6.55 | $13.06 | +1% | Neutral | |
| $3.71 | $8.26 | $18.10 | +27% | Bullish | |
| $9.18 | $20.40 | $46.92 | +215% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.25 | $6.48 | $7.83 | +0.00% |
| September 2026 | $5.02 | $6.10 | $7.74 | -5.85% |
| October 2026 | $5.29 | $6.52 | $8.44 | +6.87% |
| November 2026 | $5.60 | $6.98 | $9.18 | +7.01% |
| December 2026 | $5.39 | $6.79 | $9.06 | -2.66% |
Click any year to see its month-by-month UPC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, UPC could reach as high as $9.06, with a base case around $6.48 and support toward $2.25 — roughly 0% from $6.48. A consolidation phase looks the most probable path here.
Expect UPC to range from $3.89 to $7.91 through 2027. The $5.33 average target implies a -18% move from current prices. That is -18% versus the projected 2026 average. A cyclical pullback looks likely — prices rarely move in a straight line.
The UPC price prediction for 2028 points to an average of $5.61 (low $3.84, high $8.87) — a potential decline of -13% on today's $6.48. A consolidation phase looks the most probable path here.
In 2029, UPC is projected to trade between $3.67 and $9.39, averaging $5.65 — a potential decline of -13% from today's $6.48. That is up +1% on the projected 2028 average. Price action looks broadly range-bound.
Universe Pharmaceuticals INC's 2030 outlook centres on $7.56, within a $4.69 to $13.09 range. That is up +34% on the projected 2029 average. That marks a +17% change versus current levels. A consolidation phase looks the most probable path here.
By 2031, UPC could reach as high as $16.08, with a base case around $8.97 and support toward $5.32 — roughly +38% from $6.48. Momentum favours further upside here.
Expect UPC to range from $3.99 to $12.99 through 2032. The $7.03 average target implies a +8% move from current prices. That is -22% versus the projected 2031 average. A consolidation phase looks the most probable path here.
The UPC price prediction for 2033 points to an average of $6.85 (low $3.74, high $13.02) — a potential gain of +6% on today's $6.48. Price action looks broadly range-bound.
In 2034, UPC is projected to trade between $3.85 and $14.31, averaging $7.34 — a potential gain of +13% from today's $6.48. That is up +7% on the projected 2033 average. A consolidation phase looks the most probable path here.
Universe Pharmaceuticals INC's 2035 outlook centres on $6.55, within a $3.30 to $13.06 range. That is -11% versus the projected 2034 average. That marks a +1% change versus current levels. Price action looks broadly range-bound.
By 2040, UPC could reach as high as $18.10, with a base case around $8.26 and support toward $3.71 — roughly +27% from $6.48. Buyers look set to stay in control over this stretch.
Expect UPC to range from $9.18 to $46.92 through 2050. The $20.40 average target implies a +215% move from current prices. That is up +147% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in UPC today (≈ 154.320988 UPC) could be worth
$3,147.88
+$2,147.88 (+215%) by 2050 · US Dollar
Based on the average projected UPC price of $20.4 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in UPCwould be worth at today's price.
$1,000 invested in UPC on Jul 31, 2025 (≈ 282.725478 UPC) would be worth
$1,832.06
+$832.06 (+83.2%) today · 1.83× · US Dollar
Based on a UPC entry price of $3.54 vs. today's $6.48.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.39 | $1,911.5 | +91.2% |
| 1 month ago | $5.56 | $1,165.47 | +16.5% |
| 3 months ago | $3.21 | $2,018.69 | +101.9% |
| 6 months ago | $4.41 | $1,469.39 | +46.9% |
| 1 year ago | $3.54 | $1,832.06 | +83.2% |
| All time (5.0y) ago | $9,432 | $0.69 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our UPC forecast.
Our base-case forecast reaches $13.00 around 2050.
Implied market cap at $13.00: $8.21M
Looking further out, the forecast lays out a path of mixed but increasingly positive momentum.
By 2030, the min is $2.52, the avg is $4.07, the max is $7.05, with an ROI of 20 and a Neutral sentiment. In 2031, the min is $2.78, the avg is $4.69, the max is $8.42, with an ROI of 38.3 and a Bullish sentiment. In 2040, the min is $1.94, the avg is $4.32, the max is $9.48, with an ROI of 27.4 and a Bullish sentiment.
By 2050, the min is $4.83, the avg is $10.74, the max is $24.70, with an ROI of 216.8 and a Bullish sentiment. The forecast also shows negative returns in 2027 (-16.8), 2028 (-14.3), and 2029 (-12.4), highlighting near-term downside risk amid a longer-term upside trajectory.
These are estimates, not guarantees, and the actual outcomes may differ due to a range of market and company-specific factors.
Tap a question to reveal the answer.
In 2030 the forecast shows min $2.52, avg $4.07, max $7.05, ROI 20, sentiment NEUTRAL.
The long-run view shows bullish potential with 2050 avg $10.74 and ROI 216.8, but there are negative years in 2027-2029 (ROI -16.8, -14.3, -12.4), so outcomes are not guaranteed.
Yes—the 2050 forecast lists avg $10.74 and max $24.70, indicating potential to reach around $10 in the long term.
Current price $3.39; Market cap $2.25M.
30-day range is $1.86 to $6.17; RSI14 is 50; SMA50 is $3.89; SMA200 is $3.79; Support is $2.84 and Resistance is $12.18.
Universe Pharmaceuticals INC Community Discussion
0Share your Universe Pharmaceuticals INC price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.